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intestinal uptake of  dietary and biliary cholesterol. It was 
approved by the FDA in 2002 for hypercholesterolemia 
alone or associated with statins. Since then, the use of  
ezetimibe has increased, especially in the United States[1]. 
Some guidelines suggest that ezetimibe may become the 
first choice for patients who do not tolerate statins[2]. 
Randomized clinical trials showed that ezetimibe caused 
significant liver function abnormalities in 1% of  the 
treatment group. These changes were asymptomatic and 
entirely reversible. We report a case of  serious hepatitis 
secondary to ezetimibe.
CASE REPORT
A 56-year-old woman was admitted because of  pain-
less jaundice and pruritus. Her past medical history 
revealed essential hypertension, uterine myoma and a 
hiatal hernia. She never consumed more than 1 alcoholic 
drink per day. In the last three years, her medication 
was unchanged and consisted of  bisoprolol 10 mg/d 
and omeprazol 20 mg/d. Because of  persistent hyper-
cholesterolemia, her family doctor prescribed ezetimibe 
10 mg/d for 4 mo before admission. She was referred to 
our unit because of  apparition of  jaundice, a progressive 
scretching and liver test abnormalities. 
At physical exam, there was intense jaundice and 
some scraping lesions. Her liver was not palpable and 
there were no further abnormalities. Laboratory in-
vestigation showed the following results: aspartate 
transaminase, 16.64 kat/L (normal, < 0.5 μkat/L); 
alanine transaminase, 26.26 μkat/L (normal, < 0.56 
μkat/L); γ-glutamyl transferase, 1.15 μkat/L (normal, < 
0.43 μkat/L); alkaline phosphatase, 1.9 μkat/L (normal, 
< 1.5 μkat/L); total bilirubin, 602 μmol/L (normal, < 
18 μmol/L). Blood count, prothrombin time and kid-
ney function test were normal. Viral serology tests were 
negative (hepatitis A, B, C, Epstein-Barr virus, Herpes 
virus, HIV and cytomegalovirus). Autoimmune serology 
(antinuclear, antimitochondrial, anti-liver-kidney micro-
somal and anti-smooth muscle) was all negative. At ultra-
sonography, the liver showed no abnormality and biliary 
obstruction was disclosed. 
Ezetimibe was stopped. Jaundice and pruritus im-
proved slowly as well as laboratory results. Four weeks 
later a laboratory exam was completely normal.
DISCUSSION
The temporal association, the improvement after 
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Abstract
Ezetimibe is the first member of a new family of lipid-
lowering drugs that inhibits uptake of dietary and bili-
ary cholesterol. It was approved by the FDA in 2002 
for hypercholesterolemia alone or in combination with 
statins. Its use has been spreading over the last years. 
Ezetimibe was considered a safe drug. We report a case 
of a woman who developed a serious hepatocellular 
drug-induced liver disease after 4 mo therapy with 10 
mg daily of ezetimibe. After withdrawal of the drug, the 
patient recovered slowly. Ezetimibe may produce seri-
ous toxic hepatitis and prompt withdrawal is mandatory 
in case of a significant abnormality in liver testing after 
beginning or during treatment with ezetimibe.
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INTRODUCTION
Ezetimibe is the first lipid-lowering drug that inhibits 
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cessation of  the drug and the exclusion of  alternative 
possible causes permit us to diagnose ezetimibe-induced 
hepatotoxicity with confidence. Although rechallenge 
with the same drug could give us a definitive diagnosis, 
the clinical severity of  the hepatitis made us exclude this 
possibility. Liver biopsy can suggest hepatotoxicity or 
exclude alternative diagnoses but it was not performed 
in this case.
Ezetimibe does not affect the cytochrome P450 
system; it undergoes extensive glucuronidation in the 
wall of  the small intestine and liver to form the active 
metabolite ezetimibe glucuronide. Ezetimibe does 
not induce or inhibit enzyme systems in the liver but 
undergoes enterohepatic circulation and is exposed to 
the liver and bile. 
Statins rarely cause clinically significant liver injury, 
although asymptomatic elevations in aminotransferases 
are common. It has been suggested that this laboratory 
abnormality may result from muscle damage and not 
by hepatic injury[3]. Ezetimibe does not interfere with 
plasma levels of  HMG-coA reductase inhibitors such as 
atorvastatin and simvastatin. Association of  ezetimibe 
and statins does not lead to an apparent increase of  he-
patic side effects. Ezetimibe was expected to be even less 
hepatotoxic than statins and has been considered a safe 
drug. Nevertheless, it should be kept in mind that in a 
newly marketed drug, finding hepatotoxicity with an in-
cidence of  1:10 000 (the approximate incidence of  most 
idiosyncratic reactions) would require 30 000 patients 
treated with this drug[4]. 
The pattern of  drug-related liver injury can be clas-
sified in hepatocellular, cholestatic or mixed according 
to laboratory data[5]. Until now, four cases of  significant 
drug-induced liver injury associated with ezetimibe have 
been reported[6-8], three of  them associated with atorvas-
tatin. One case was a cholestatic type, another one was 
hepatocellular and the last two were drug-induced acute 
autoimmune hepatitis. Our patient presented as serious 
hepatocellular hepatitis[9]. Patients with acute toxic hepa-
tocellular damage are at high risk of  acute liver failure. 
Mortality, or its surrogate marker, liver transplantation, is 
superior to 10%; this is known as “Hy’s rule”.  
Although causes of  ezetimibe toxicity are unclear, 
apart from an idiosyncratic drug reaction, it could be 
hypothesized that a conjugation defect leads to accumu-
lation of  toxic levels of  ezetimibe or their metabolites. 
As hepatotoxicity by ezetimibe has been reported in dif-
ferent types according to laboratory data, several mecha-
nisms may be implied. 
The current recommendation to monitor liver func-
tion after beginning therapy with statins is controversial 
with some experts calling for its re-examination. Ezeti-
mibe, alone or associated to statins, may produce serious 
toxic hepatitis. Caution should be taken and the neces-
sity of  analytical follow-up after beginning or during the 
treatment with ezetimibe is unknown. A prompt with-
drawal of  the drug is mandatory in case of  a significant 
abnormality in liver tests.
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